ClinicalTrials.gg
Not yet recruitingNCT07095855Updated Aug 3, 2025

A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB

A Phase 3 interventional study of ZM-H1505R 100mg and ZM-H1505R Placebo in Chronic Hepatitis B, sponsored by Shanghai Zhimeng Biopharma, Inc.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-03.

Sponsored by Shanghai Zhimeng Biopharma, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,300
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 375 studies in Hepatitis B, Chronic with a site in China — 89 open to participants now, 110 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Planned enrollment
13th of 273
1,300 · median 120
Started
2025
with 22 others
Phase 3
26 of 375
5 open now
Primary completion
2028-01
later than 85 of 109 live
Registered
327th of 375
by date

Among the 375 studies in Hepatitis B, Chronic with a site in China, this one is the 13th largest by planned enrollment of the 273 interventional ones that give a count, is one of 23 that started in 2025, is one of 26 in phase 3, reaches primary completion later than 85 of the 109 other live ones, and was the 327th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

89 of the 375 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

84 more — sign in →

All 89 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 375 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

This study is divided into two parts. Part A is a multicenter, randomized, double-blind, placebo controlled phase Ill clinical trial, designed to evaluate the efficacy and safety of ZM-H1505R in combination with NAs versus NAs monotherapy with HBV DNA ≥ 50 IU/mL and are HBeAg positive who have received NAs monotherapy for at least 12months.Part B is an open-label extension and follow-up period designed to evaluate the long-term safety and efficacy of ZM-H1505R in combination with NAs.

Read the detailed description

This study is divided into two parts. Part A is a multicenter, randomized, double-blind, placebo controlled phase Ill clinical trial, designed to evaluate the efficacy and safety of ZM-H1505R in combination with NAs versus NAs monotherapy with HBV DNA ≥ 50 IU/mL and are HBeAg positive who have received NAs monotherapy for at least 12months.Part B is an open-label extension and follow-up period designed to evaluate the long-term safety and efficacy of ZM-H1505R in combination with NAs.

- Part A (Double-Blind Treatment Period): Eligible subjects will be randomized in a 1:1 ratio into 2 groups. Group A:ZM-H1505R 100mg +NAs Group B:ZM-H1505R placebo +NAs Two randomization stratification factors were set: NAs type of ETV, TDF,TAF, or TMF (no less than 15% of ETV, TDF, and TAF); HBV DNA \<2000 IU/mL and HBV DNA >2000 IU/mL . All subjects completed a 48-week efficacy and safety evaluation followed by an interim analysis, the results of which were used to submit an NDA application.

- Part B (Open-Label Extension Period): At the end of the 48-week randomized double-blind treatment period, all eligible subjects will transfer to the open-label extension period and were treated with ZM-H1505R 100 mg +NAs while the study drug was evaluated for efficacy and safety until the end of the 144 weeks.

- Follow-up Period: At the end of the 144-week open-label extension period, all subjects will continue to take NAs, as a monotherapy for a 4-week follow-up period for observation of efficacy and safety of after discontinuation of study drug in ZM-H1505R .

03

Conditions studied

  • Chronic Hepatitis B

Keywords

  • ZM-H1505R
  • Hepatitis B
  • CHB
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Able to understand and sign the written form;
  • 2.Adult males and females aged 18-65 years(inclusive) at screening;
  • 3.Have been used NAs monotherapy with ETV(0.5 mg or 1.0mg, QD),TDF (300 mg, QD),TAF (25 mg, QD),or TMF (25 mg, OD)for at least 12 months at the time of enrollment; Have been on stable and continuous use of one of these medications for at least 6months, and do not plan to switch to any other NAs class of medications after entering this clinical trial;
  • 4.Evidence of prior infection (e.g., HBsAg and/or HBV DNA positive), or HBsAg positive at screening;
  • 5.HBV DNA ≥50 IU/mL as measured by a local healthcare facility within 30 days prior to screening and HBV DNA ≥50 IU/mL as confirmed by central laboratory testing at the time of screening;
  • 6.HBeAg positivity confirmed by central laboratory testing at screening;
  • 7.Women of or males with female partners of childbearing potential must agree to voluntarily use the methods specified in the protocol from screening to 28 days after the last dose of the study.

Exclusion criteria

Exclusion Criteria:

  • 1.Progressive fibrosis or cirrhosis detected at screening, or progressive fibrosis or cirrhosis defined as follows: Metavir ≥ 3 or Ishak fibrosis score ≥ 4 by liver within 1 year prior to screening; or in the absence of an appropriate liver biopsy, liver stiffness test (FibroScan) ≥ 9 kPa within 3 months prior to screening, or liver stiffness test (FibroTouch) ≥ 9.6 kPa(FibroScan preferred) ;
  • 2.History of hepatocellular carcinoma (HCC); or serum alpha-fetoprotein (AFP) ≥ 50 ng/mL at screening, or imaging examination such as abdominal ultrasound, CT (computed tomography) or MRI (magnetic resonance imaging) suggesting possible HCC;
  • 3.Subjects meeting any of the following clinical laboratory parameters at screening:

    1. \< 110 g/L (for males) or \< 100 g/L (for females);
    2. count \< 90 × 109/L;
    3. \< 1.5 × 109/L;
    4. (ALT) or Aspartate aminotransferase(AST)> 3 × (×ULN);
    5. (INR) of prothrombin time > 1.3;
    6. Albumin \< 35 g/L;
    7. Total > 2 × ULN, and direct bilirubin > 1.5 × ULN;
    8. Estimated \< 60 mL/min/1.73 m2(calculated using the CKD-MDRD formula).
  • 4.Abnormal result of (ECG) at screening and inappropriate for the study participation judged by the investigator; or (QT corrected using the Fridericia formula): > 450 ms for males, > 470 ms for females at screening;
  • 5.Co-infection with (HIV), hepatitis A virus (HAV), virus (HCV), hepatitis D virus (HDV) or hepatitis E virus (HEV); Note: Subjects with positive HCV antibody (Ab) but negative HCV RNA and subjects with positive HEV immunoglobulin M (IgM) but negative HEV RNA will NOT be excluded.
  • 6.Other unless the subject's malignancy has been cured by surgical resection (e.g., basal cell skin cancer); Note: Subjects who are suspected of having malignancy must be excluded regardless of evidence of local recurrence or .
  • 7.History of chronic liver disease with a non- etiology, such as alcoholic liver disease, liver disease, hereditary liver disease, non-alcoholic fatty liver disease, except for simple fatty liver disease;
  • 8.Other concurrent severe systemic diseases or clinical manifestations, for which the investigator considers not suitable to participate in this study;
  • 9.Use of any product or drug not approved by regulatory authorities within 3 months prior to screening;
  • 10.History of persistent alcohol consumption (alcohol consumption exceeding 40 g ethanol for males or 20g ethanol for females per day on average) within 6 months prior to screening;
  • 11.History of drug dependence or drug abuse;
  • 12.Pregnant or breastfeeding women;
  • 13.Known to the active ingredient or formulation of the investigational drug;
  • 14.Inappropriate for the study participation for any reason not otherwise listed as judged by the investigator.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,300 participants (estimated)

Study arms

  • Experimental
    Group A:ZM-H1505R + NAs

    ZM-H1505R 100mg,QD + NAs(ETV or TDF or TAF or TMF)

    Drug: ZM-H1505R 100mg · Combination Product: NAs ("Entecavir"or"Tenofovir"or"Tenofovir alafenamide"or"TMF") treatments

  • Placebo comparator
    Group B: ZM-H1505R Placebo + NAs

    ZM-H1505R Placebo 100mg,QD + NAs(ETV or TDF or TAF or TMF)

    Other: ZM-H1505R Placebo · Combination Product: NAs ("Entecavir"or"Tenofovir"or"Tenofovir alafenamide"or"TMF") treatments

Interventions

  • DrugZM-H1505R 100mg

    ZM-H1505R(100mg,QD) will be used in Part A double-blind treatment period for 48 weeks and Part B open-label extension period 144 weeks.

  • OtherZM-H1505R Placebo

    ZM-H1505R Placebo(100mg,QD) will be used in Part A double-blind treatment period for 48 weeks.

  • Combination productNAs ("Entecavir"or"Tenofovir"or"Tenofovir alafenamide"or"TMF") treatments

    All eligible subjects will be use NAs ("Entecavir"or"Tenofovir"or"Tenofovir alafenamide"or"TMF") treatments during the study for 148 weeks, including Part A and Part B. Subjects will continue to use the NAs as combination therapy before enrollment, the dosage will not be adjusted during the study. Subjects use in accordance with medical advice andinstructions.

06

What researchers measure

Primary outcomes

  1. Percentage of subjects achieves complete virologic response (CVR) at week 48 of treatment.

    To evaluate the efficacy of ZM-H1505R in combination with NAs versus NAs monotherapy in adult CHB subjects who have received NAs monotherapy for at least 12 months. (CVR is defined as HBV DNA ≤ 10 IU/mL)

    Time frame: 48 week

Secondary outcomes

  1. Safety of ZM-H1505R in combination with NAs versus NAs monotherapy in adult CHB subjects who have received NAs monotherapy for at least 12 months.

    Safety during the 48-week double-blind treatment period, the open-label extension period, and the follow-up period.

    Time frame: From baseline to the end of follow-up period(Part A and Part B), assessed up to 148 weeks.

  2. Percentage of subjects who achieve CVR at each scheduled visit other than week 48 visit

    CVR is defined as HBV DNA ≤ 10 IU/mL).

    Time frame: Part A(double-blind treatment period):from baseline to week 48; Part B (open-label extension period and follow-up period):from week 48 to week 148.

  3. Time to achieve CVR in each group

    CVR is defined as HBV DNA ≤ 10 IU/mL

    Time frame: Part A(double-blind treatment period):from baseline to week 48

  4. Percentage of subjects with quantitative HBV DNA ≤ 20 IU/mL

    Time frame: Part A(double-blind treatment period):from baseline to week 48; Part B (open-label extension period and follow-up period):from week 48 to week 148.

  5. Changes from baseline in quantitative HBV RNA

    Time frame: Part A(double-blind treatment period):from baseline to week 48; Part B (open-label extension period and follow-up period):from week 48 to week 148.

  6. Percentage of subjects who achieve LLOQ of quantitative HBV RNA

    Time frame: Part A(double-blind treatment period):from baseline to week 48; Part B (open-label extension period and follow-up period):from week 48 to week 148.

  7. Changes from baseline in quantitative serum HBsAg

    Time frame: Part A(double-blind treatment period):from baseline to week 48; Part B (open-label extension period and follow-up period):from week 48 to week 148.

  8. Changes from baseline in HBeAg at each scheduled visit

    Time frame: Part A(double-blind treatment period):from baseline to week 48; Part B (open-label extension period and follow-up period):from week 48 to week 148.

  9. Changes from baseline in quantitative serum HBcrAg at each scheduled visit;

    Time frame: Part A(double-blind treatment period):from baseline to week 48; Part B (open-label extension period and follow-up period):from week 48 to week 148.

  10. Changes from baseline in liver stiffness test (FibroScan/FibroTouch)

    Time frame: Part A(double-blind treatment period):at week24 and week 48; Part B (open-label extension period and follow-up period):from week 48 to week 148.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Jan 2028, 29 months later.

Of 24 phase 3 interventional studies under Hepatitis B, Chronic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's planned 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2025
First posted
Jul 31, 2025
StartEst.
Aug 2025
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2030
Last update
Aug 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07095855
Lead sponsor
Shanghai Zhimeng Biopharma, Inc.
Responsible party
Sponsor
First posted
Jul 31, 2025
Start date
Aug 2025 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
Jan 2030 (estimated)
Last update
Aug 3, 2025

Study contacts

Project Manager
Contact
adeng@corebiopharma.com
+8615800984667

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion